Develops inhalation therapies for lung diseases and disorders.
TFF Pharmaceuticals, Inc. is a dynamic clinical stage biopharmaceutical firm specializing in the advancement and commercialization of novel drug products leveraging its proprietary Thin Film Freezing (TFF) technology platform. Operating primarily in the United States and Australia, TFF Pharma focuses on pioneering inhaled dry powder drugs tailored for the treatment of various pulmonary diseases and conditions. At the forefront of its pipeline are promising candidates like TFF Voriconazole Inhalation Powder and TFF Tacrolimus Inhalation Powder, currently undergoing Phase II clinical trials. These innovations aim to address critical medical needs such as invasive pulmonary aspergillosis and lung transplant rejection prevention.
Beyond its lead programs, TFF Pharmaceuticals is actively developing a diverse array of dry powder products. These include formulations like cannabidiol for epilepsy syndromes, anxiety, insomnia, and pain management. Additionally, the company is advancing Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 treatment and Niclosamide Inhalation Powder for tapeworm infections and COVID-19 disease. TFF Pharma collaborates extensively through strategic alliances, including a license agreement with the University of Texas at Austin and a joint development initiative with Augmenta Bioworks, Inc. for inhaled SARS-CoV2 monoclonal antibodies. Furthermore, it has forged a significant licensing and collaboration agreement with UNION therapeutics A/S.
Established in 2018 and headquartered in Austin, Texas, TFF Pharmaceuticals, Inc. exemplifies a commitment to innovation in respiratory medicine and beyond. With a robust technology platform and a comprehensive pipeline targeting diverse therapeutic areas, TFF Pharma is poised to make substantial contributions to healthcare by enhancing drug delivery efficacy and patient outcomes on a global scale.